MedTrace Logo

Effect of Losartan on Airway Mucociliary Dysfunction in Patients With COPD and Chronic Bronchitis

NCT02416102 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2020-08-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effect of Losartan on cigarette smoke-induced lung injury in smokers and ex-smokers with and without chronic obstructive pulmonary disease (COPD).

Conditions

  • COPD
  • Chronic Bronchitis

Interventions

DRUG

Losartan 50 mg

50 mg Losartan taken orally once daily for 4 consecutive weeks.

DRUG

Losartan 100 mg

50 mg Losartan taken orally twice daily for 4 consecutive weeks.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Flight Attendant Medical Research Institute

    collaborator OTHER

  • University of Miami

    lead OTHER

Principal Investigators

  • Rafael Calderon, MD · University of Miami

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-04-03
Completion
2017-04-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02416102 on ClinicalTrials.gov